AFT gains Australian registration for intravenous Maxigesic

AFT gains Australian registration for intravenous Maxigesic
Jenny Ruth
By Jenny Ruth July 24 (BusinessDesk) - AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration. The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution. The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, Sou...

More Services

Anna Scott joining Mercer
Markets

Anna Scott joining Mercer

Former Smart boss will replace current Mercer chief executive Martin Lewington.

Staff reporters 03 Jul 2025
Aussie fund manager Shaws buys Devon Funds
Finance

Aussie fund manager Shaws buys Devon Funds

The deal is the latest tie-up between Australian and NZ funds managers.

Staff reporters 24 Jun 2025
Buy NZ Made's new service trademark sets high bar
Services

Buy NZ Made's new service trademark sets high bar

One certified business says it sets it apart from multinational competitors.

John Anthony 23 Jun 2025
Reel pain: Strikes hit NZ cinemas, profits dive
Services

Reel pain: Strikes hit NZ cinemas, profits dive

Cinema chains in NZ face box office suspense.

Victoria Young 28 May 2025